

Press Release.

Opella exceeds its 2025 sustainability goals and launches Health³ - its new strategy.

17 June 2026 – Opella, the global consumer healthcare company behind world-leading brands including Allegra, Buscopan and Doliprane, today launches Health³ - a new sustainability program marking the next chapter in how it approaches environmental, social and business responsibility. Built on the principle that impact is achieved through the multiplying effect of three interconnected pillars, Healthy Planet x Healthy People x Healthy Business - Health³ represents Opella's most ambitious sustainability commitment yet.

The launch of Health³ follows Opella's achievement of all 2025 sustainability targets:¹

- -65% Scopes 1 and 2 emissions versus 2019, achieving -70%.
- 100% renewable electricity in operations.
- 100% landfill-free manufacturing sites for eligible sites.
- 100% paper-based consumer packaging from certified sources.
- 100M people reached annually on health awareness and responsible medicine use, reaching 238M in 2025.

Healthy Planet: Leading Climate Action.

Climate change is not just an environmental issue; it is a health crisis. Recognizing this urgent need to act and given that 97% of Opella's emissions come from the company's value chain, long-term structural decarbonization is a strategic priority. Opella will work towards achieving net-zero by 2050, with a near-term target of reducing absolute emissions across Scopes 1, 2, and 3 by 58.8% by 2034.² These targets have been validated by the Science Based Targets initiative (SBTi) in 2025, and this approach is critical for the healthcare industry, which is responsible for nearly 5% of global emissions.³

Healthy People: Expanding Health Impact.

Self-care is one of the most powerful levers available to reduce pressure on healthcare systems and on the planet. In Europe alone, an estimated 1.2 billion minor ailments are self-managed each year using non-prescription medicines, saving more than 13 billion individual hours in travel and waiting time and 2.2 billion hours of physician time.⁴ But good self-care depends on society having a strong understanding of their health, yet this gap remains significant. That is why Opella aims to improve health literacy for 50 million people annually and train 200,000 pharmacists by 2030.

Healthy Business: Strengthening Ethical Leadership.

As the first global consumer health company to achieve B Corp certification⁵, Opella holds itself to high sustainability standards. Opella reaffirms this by working towards B Corp recertification under B Lab's new stringent standards with five-year requirements. Working toward this milestone will ensure continuous improvement at Opella across sustainability criteria.

Marissa Saretsky, Chief Sustainability Officer.

"We stand at an inflection point where interconnected global challenges demand interconnected solutions. Climate risks and social inequities are amplified by one another, creating cascading effects that no single intervention can solve. Health³ is our commitment to systemic transformation, recognising that when we multiply our efforts across planet, people and business, we don't just add value, we exponentially increase our ability to address the world's pressing challenges."

About Opella.

Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health in people's hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting. At the core of this mission is our 100 loved brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world's most loved brands,

including Allegra, Buscopan, Doliprane, Dulcolax, Enterogermina, Essentiale and Mucosolvan. B Corp certified globally, we are active players in the journey towards healthier people and planet.

Find out more about our mission at www.opella.com.

Press Contact.

Justine Rohée. justine.rohee@opella.com. +33 6 86 47 85 60.

Natacha Kalasa. natacha.kalasa@opella.com. +33 6 72 16 64 61.

All trademarks mentioned in this press release are the property of Opella.

- 1 For details about data, methodology, and definitions, please visit our 2025 Sustainability Report available on Opella.com.
- 2 Opella's Scope 3 emissions reduction target covers the following categories: purchased goods and services, upstream transportation and distribution, and business travel.
- 3 4.4% in 2014 according to Healthcare Without Harm: https://global.noharm.org/sites/default/files/documents-files/5961/HealthCaresClimateFootprint_092319.pdf
- 4 "Self-care socio-economic research" - GSCF - February 2026.
- 5 For the purposes of this release, a "global consumer healthcare company" is defined as an entity operating across multiple major international markets (including North America, Europe, Asia-Pacific, and Latin America), with a diversified OTC product portfolio and annual consumer healthcare revenues exceeding USD \$2 billion. This definition aligns with industry standards such as those recognized by Nicholas Hall.